Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis

Author： Schmidt H.   Woodcock B.G.   Geisslinger G.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.27, Iss.3, 2004-01, pp. : 185-196

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer

By Dienstmann Rodrigo  

Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. : 15-25

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Levetiracetam in the Treatment of Partial Seizures

By Abou-Khalil Bassel  

Drug Safety, Vol. 28, Iss. 10, 2005-01 ,pp. : 871-890

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis

By Mikuls T.R.  

Drug Safety, Vol. 26, Iss. 1, 2003-01 ,pp. : 23-32

Adis International

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Dapoxetine in the Treatment of Premature Ejaculation

By Hutchinson Kate   Cruickshank Kelly   Wylie Kevan  

Drug Safety, Vol. 35, Iss. 5, 2012-05 ,pp. : 359-372

Adis International

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Medical Treatment for Uterine Leiomyomas

By De Leo V.   Morgante G.   La Marca A.   Musacchio M.C.   Sorace M.   Cavicchioli C.   Petraglia F.  

Drug Safety, Vol. 25, Iss. 11, 2002-01 ,pp. : 759-779

Adis International

Access to resources Recommend Favorite